REG - Imaging Biometrics - Expansion Global Distribution Agreement with GE

Imaging BiometricsAnnouncement

10/12/2025 09:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251210:nRSJ0116La&default-theme=true

RNS Number : 0116L  Imaging Biometrics Limited  10 December 2025

December 10, 2025

Imaging Biometrics, Ltd

("IBAI" or the "Company")

 

Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to
Include FTB Express Maps and QSMetric™

 

Imaging Biometrics (IB), a leader in advanced neuroimaging solutions,
announces an amendment to its distribution agreement with GE HealthCare,
expanding access to two innovative offerings: FTB Express maps and QSMetric.

 

The agreement already includes IB Neuro and Delta T1 maps, widely adopted
together to assist clinicians in diagnosing, planning, and monitoring
treatment response for brain tumor patients. Delta T1 maps provide rapid,
objective delineation of contrast-enhancing regions, while IB Neuro generates
standardized (quantitative) MR DSC perfusion images of relative cerebral blood
volume (sRCBV), which eliminates manual tissue normalization. These outputs
serve as inputs for Fractional Tumor Burden (FTB) maps, which deliver
automated visualization of tumor versus non-tumor tissue and treatment effects
within enhancing regions. FTB Express accelerates this process, enabling
clinicians to quickly access actionable insights for patient care.

 

QSMetric is a patented quantitative susceptibility mapping software that
processes gradient echo brain images to visualize tissue structures and
measure susceptibility values. This capability supports a broad range of
clinical applications, including targeting for deep brain stimulation (DBS)
surgery, neurodegenerative disease assessment, multiple sclerosis, and more.

 

Katie Anderson, Global MR Visualization Product Manager at GE HealthCare,
said, "We are excited to expand our collaboration with Imaging Biometrics to
enable access for our customers to these clinically important capabilities."

 

--ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

For further information, please contact:

 

 Imaging Biometrics Ltd

 Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 AlbR Capital Limited (Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

 

 

About Imaging Biometrics® LLC

IB is a wholly owned subsidiary of Imaging Biometrics, Ltd, (LON: IBAI), and
focuses on delivering quantitative imaging platforms and therapeutics that
transform how clinicians diagnose and treat patients more efficiently and
effectively. For more information about Imaging Biometrics, visit the
company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com/) . Follow IB on X @ImgBiometrics.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDZMMZLGMGKZG



            Copyright 2019 Regulatory News Service, all rights reserved